Translation 538,061

PATENT COOPERATION TREATY

PCT/JP2003/015794

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

	(PCT Article 36 and Rule 70)
Applicant's or agent's file reference	
A31654M	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)
International application No. * PCT/JP2003/015794	International filing date (day/month/year) Priority date (1.4
	10 December 2003 (10.12.2002)
International Patent Classification (IPC) or na A61K 45/06, 31/138, 31/167, 31/	otional al. 19 19 19 19 19 19 19 19 19 19 19 19 19
Applicant	
SF	HOWA YAKUHIN KAKO CO., LTD.
2. This REPORT consists of a total of _	4 sheets, including this cover sheet.
This report is also accompanied amended and are the basis for the 70.16 and Section 607 of the Action	I by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been this report and/or sheets containing rectifications made before this Authority (see Rule dministrative Instructions under the PCT).
These annexes consist of a total	of sheets.
3. This report contains indications relating	g to the following items:
I Basis of the report	
II Priority	
III Non-establishment of o	pinion with regard to novelty, inventive step and industrial applicability
IV Lack of unity of inventi	on
V Reasoned statement und citations and explanation	ler Article 35(2) with regard to novelty, inventive step or industrial applicability;
VI Certain documents cited	2
VII Certain defects in the int	ternational application
	the international application
te of submission of the demand	D. C.
10 December 2003 (10.12.20	Date of completion of this report
	02 July 2004 (02.07.2004)
me and mailing address of the IPEA/JP	Authorized officer
simile No.	
DCT/DD 4 (400)	Telephone No.

Form PCT/IPEA/409 (cover sheet) (July 1998)

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/JP2003/015794

I. Basis of the report	1 C1/3F2003/015/94
1. With regard to the elements of the international application:*	
the international application as originally filed	
the description:	
pages	, as originally filed
	filed with the doment
, filed with the letter	r of
the claims:	
pages	, as originally filed
, as amended (to	ogether with any statement under Article 19
pages	filed with the demand
pages, filed with the letter	of
the drawings:	
pagespages	, as originally filed
	filed with the demand
pages, filed with the letter	of
the sequence listing part of the description:	
pages	
pages	61 1 1 1
pages, filed with the letter	of
 With regard to the language, all the elements marked above were available or furnished the international application was filed, unless otherwise indicated under this item. These elements were available or furnished to this Authority in the following language the language of a translation furnished for the purposes of international search (under the language of publication of the international application (under Rule 48.3(b)). The language of the translation furnished for the purposes of international prelim or 55.3). With regard to any nucleotide and/or amino acid sequence disclosed in the international preliminary examination was carried out on the basis of the sequence listing: contained in the international application in written form. filed together with the international application in computer readable form. furnished subsequently to this Authority in written form. furnished subsequently to this Authority in computer readable form. The statement that the subsequently furnished written sequence listing does international application as filed has been furnished. The statement that the information recorded in computer readable form is identified been furnished. The amendments have resulted in the cancellation of: 	which is: der Rule 23.1(b)). unary examination (under Rule 55.2 and/ ternational application, the international
the description, pages the claims, Nos. the drawings, sheets/fig This report has been established as if (some of) the amendments had not been made beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).* * Replacement sheets which have been furnished to the receiving Office in response to an in this report as "originally filed" and are not annexed to this report since they do and 70.17). ** Any replacement sheet containing such amendments must be referred to under item 1 and an	vitation under Article 14 are referred to not contain amendments (Rule 70.16
Form PCT/IPEA/409 (Box I) (July 1998)	

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/JP 03/15794

Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement				
Statement			-	
Novelty (N)	Claims	2, 6, 7	YES	
	Claims	1, 3-5	NO	
Inventive step (IS)	Claims	2, 6, 7	YES	
	Claims	1, 3-5	NO	
Industrial applicability (IA)	Claims	1-7	YES	
	Claims		NO NO	

2. Citations and explanations

- Document 1: JP 11-228398 A (Hisamitsu Pharmaceutical Co., Ltd.), 24 August 1999
- Document 2: JP 7-291856 A (Yutoku Pharnaceutical Ind. Co., Ltd.), 7 November 1995
- Document 3: JP 3-291221 A (Otsuka Pharmaceutical Factory, Inc.), 20 December 1991
- Document 4: Journal of the American Pharmaceutical Association (1912-1977), 1954, Vol. 43, pp. 263-266 (abstract); CAplus Accession No. 1954:47432
- Document 5: WO 02/055107 Al (Showa Yakuhin Kako Co., Ltd.), 18 July 2002
- Document 6: WO 97/07794 A1 (Showa Yakuhin Kako Co., Ltd.), 6 March 1997 & EP 858803 A1

Claims 1 and 3-5

The inventions set forth in claims 1 and 3-5 are not novel and do not involve an inventive step in the light of documents 1-3, cited in the international search report.

Documents 1-3 disclose medicinal compositions which include a local anaesthetic such as lidocaine and an antihistamine such as diphenhydramine, and substantially do not contain catecholamines. These documents 1-3 do not mention incorporation in the compositions of an "agent

which sustains the anaesthetic effect"; however, the constituent which the applicant terms an "agent which sustains the anaesthetic effect" is no different as a substance from an "antihistamine", and the inventions set forth in claims 1 and 3-5 and the inventions disclosed in documents 1-3 are substantially indistinguishable as substances.

Claims 2, 6 and 7

The inventions set forth in claims 2, 6 and 7 are novel and involve an inventive step relative to documents 1-3, documents 4 and 5, cited in the international search report, and document 6, which is a patent family cited in the international search report.

None of documents 1-6 discloses or suggests an invention of a composition for surgery of the oral cavity or for dental use, or an invention of application as an "agent which sustains the action of a local anaesthetic".